Where we end up is important not the upfront.
We didn't wait all these years and kept faith for 200-300m valuation, let's be serious guys.
A licensing agreement is a reflection of trust in science by other Pharma company who have made a decision to partner after a full on due diligence and know way more about science than any of us.
I am really interested to see the deal structure as I won't be surprised to see Dimerix trading around 1bn post March results (assuming it's positive and it's a global agreement).
Ann: Trading Halt, page-9
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 46.5¢ | 44.0¢ | $1.428M | 3.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 109582 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 21213 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |